Lead Product(s) : Corallopyronin A
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : The Global Health Innovative Technology
Deal Size : $5.9 million
Deal Type : Funding
USD 10.8 Mn Invested in New Drug Development for Malaria with Japanese Pharma Partners
Details : The net proceeds will be used for the preclinical development of the macrofilaricide corallopyronin A (CorA) for the treatment of onchocerciasis and lymphatic filariasis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 05, 2024
Lead Product(s) : Corallopyronin A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : The Global Health Innovative Technology
Deal Size : $5.9 million
Deal Type : Funding
Lead Product(s) : Stenoparib
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Allarity Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Allarity Therapeutics Expands its Stenoparib License Rights to Include Anti-Viral Uses
Details : Allarity holds global, exclusive rights to the PARP inhibitor, Stenoparib, under an existing license with Eisai, in the field of cancer therapeutics and treatment. With the amendment, Allarity now further holds global, exclusive rights to the drug as an ...
Product Name : 2X-121
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 14, 2020
Lead Product(s) : Stenoparib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Allarity Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : DS-5670
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Daiichi Sankyo is set to develop a mRNA vaccine candidate to protect against Covid-19 infection in the country. The project, Fundamental Research on the Control of a Novel Coronavirus (2019-nCoV), is supported by the Japan Agency for Medical Research and...
Product Name : DS-5670
Product Type : Vaccine
Upfront Cash : Inapplicable
December 06, 2020
Lead Product(s) : DS-5670
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sosei Heptares has successfully designed three distinct series of compounds. These compounds have demonstrated high potency in inhibiting the activity of the Mpro protease as well as promising oral bioavailability and blood plasma levels in animal studie...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 20, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Japan's Shionogi Readies COVID-19 Vaccine for December Trial
Details : The company plans to put its vaccine candidate into Phase 1 clinical trials in December and shift into Phase 2 by January and apply for tentative approval from the government.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 29, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BNC-1322
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bonac to Begin Human Clinical Tests for Covid-19 Drug in 2021
Details : Governor Ogawa confirmed the effectiveness of the "nucleic acid drug" against viral infections in an experiment using a new coronavirus strain, and finished narrowing down to three types of drug candidates that could be expected to be effective even in s...
Product Name : BNC-1322
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
August 26, 2020
Lead Product(s) : BNC-1322
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Chugai, A*STAR to Develop Therapeutic Ab Against COVID-19
Details : Physicians from Keck Medicine of USC are set to launch a clinical trial to study the effects of an anti-inflammatory drug on treating patients with moderate to severe coronavirus (Covid-19).
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
August 05, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eritoran
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : The Global Coalition For Adaptive Research
Deal Size : Undisclosed
Deal Type : Partnership
Eisai to Investigate Eritoran in REMAP-COVID Study
Details : The trial will be conducted in the multi-hospital UPMC health system along with other medical centers in the United States. Additional global sites across the trial network, including Japan, will follow.
Product Name : E5564
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 07, 2020
Lead Product(s) : Eritoran
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : The Global Coalition For Adaptive Research
Deal Size : Undisclosed
Deal Type : Partnership